

PharmLabs San Diego Certificate of Analysis



Sample Reese's Pieces

Delta9 THC ND	THCa ND	Total THC (THCa + 0.877 + THC) ND	Delta8 THC ND
---------------	---------	-----------------------------------	---------------

Sample ID SD260116-019 (131578)	Matrix Edible
Tested for Sacred Journey Inc.	
Sampled -	Received Jan 16, 2026
Analyses executed CAN+, 4AD, PSY	Reported Jan 22, 2026
	Unit Mass (g) 15.224

Laboratory note: This sample contains an Unidentified Peak that PharmLabs does not currently test for. COA Update: 1/21/26 - Photo updated per client request. COA Update: 1/22/26 Tested For info updated as per client request.

CAN+ - Cannabinoids

Analyzed Jan 16, 2026 | Instrument HPLC-VWD | Method SOP-001  
The expanded Uncertainty of the Cannabinoids analysis is approximately ±7.81% at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Unit	Sample photography
Cannabidiol (CBD)	0.039	0.16	ND	ND	ND	
Cannabidiol (CBD)	0.011	0.03	ND	ND	ND	
Cannabidiolic Acid (CBDA)	0.033	0.16	ND	ND	ND	
Cannabigerol Acid (CBGA)	0.033	0.16	ND	ND	ND	
Cannabigerol (CBG)	0.048	0.16	ND	ND	ND	
Cannabidiol (CBD)	0.069	0.229	ND	ND	ND	
Tetrahydrocannabinol (THCV)	0.049	0.16	ND	ND	ND	
Cannabinol (CBN)	0.047	0.16	ND	ND	ND	
Tetrahydrocannabinol (Δ9-THC)	0.092	0.307	ND	ND	ND	
Δ8-tetrahydrocannabinol (Δ8-THC)	0.044	0.16	ND	ND	ND	
Cannabicyclol (CBL)	0.0012	0.16	ND	ND	ND	
Cannabichromene (CBC)	0.13	0.432	ND	ND	ND	
Tetrahydrocannabinolic Acid (THCA)	0.117	0.389	ND	ND	ND	
Total THC ( THCa + 0.877 + Δ9THC )			ND	ND	ND	
Total THC + Δ8THC ( THCa + 0.877 + Δ9THC + Δ8THC )			ND	ND	ND	
Total CBD ( CBDa + 0.877 + CBD )			ND	ND	ND	
Total CBG ( CBGa + 0.877 + CBG )			ND	ND	ND	
Total Cannabinoids Analyzed			ND	ND	ND	

4AD - 4AD Tryptamines

Analyzed Jan 16, 2026 | Instrument HPLC-VWD | Method SOP-4AD  
The expanded Uncertainty of the 4AD Tryptamines analysis is approximately ±7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Unit
Mescaline (MESCL)	0.19	0.584	ND	ND	ND
N-methyl Tryptamine (NMT)	0.004	0.013	ND	ND	ND
4-Hydroxy-MET (4-HO-MET)	0.013	0.04	ND	ND	ND
n,n Dimethyltryptamine (DMT)	0.015	0.048	ND	ND	ND
Psilocetin (PSLA)	0.015	0.044	ND	ND	ND
4-Hydroxy-DET (4-HO-DET)	0.014	0.042	ND	ND	ND
4-Acetoxy-MET (4-AcO-MET)	0.018	0.053	ND	ND	ND
4-Acetoxy-DET (4-AcO-DET)	0.004	0.011	ND	ND	ND
4-Bromo-DMP (2C-B)	0.19	0.576	ND	ND	ND

PSY - Psilocybin & Psilocin

Analyzed Jan 16, 2026 | Instrument HPLC-VWD | Method SOP-PSY  
The expanded Uncertainty of the Psilocybin & Psilocin analysis is approximately ±7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Unit
Psilocybin (PSCY)	0.007	0.019	ND	ND	ND
Psilocin (PSCI)	0.003	0.009	<LOQ	<LOQ	<LOQ

UI Unidentified  
ND Not Detected  
N/A Not Applicable  
NT Not Reported  
LOD Limit of Detection  
LOQ Limit of Quantification  
<LOQ Detected  
>ULOL Above upper limit of linearity  
CFU/g Colony Forming Units per 1 gram  
TNTC Too Numerous to Count



DEA license: RP0611043  
ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

*Brandon Starr*

Brandon Starr, Quality Assurance Manager  
Thu, 22 Jan 2026 14:44:41 -0800

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368



PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2019 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.